Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy
2020年1月23日 更新者:Juanita Crook、British Columbia Cancer Agency
Phase II Trial Assessing the Feasibility and Toxicity of Degarelix in Achieving Prostate Downsizing Prior to Treatment With Permanent Seed Prostate Brachytherapy
This study will investigate the efficacy of Degarelix, a Luteinizing Hormone Releasing Hormone (LHRH) antagonist, to reduce prostate volume prior to permanent seed prostate brachytherapy.
There are 2 eligible populations of men, all of whom will have selected brachytherapy as their treatment of choice for their prostate cancer.
Either they have an enlarged prostate that requires size reduction to render brachytherapy technically feasible, or they require androgen ablation in conjunction with brachytherapy for optimal tumor control.
The hypothesis is that Degarelix will provide > 30% volume reduction by 3 months in > 30% of men.
研究概览
详细说明
All men will have a baseline transrectal ultrasound for brachytherapy planning that has demonstrated an enlarged prostate with or without pubic arch obstruction.
After signing the informed consent document they will have a loading dose of 240 mg Degarelix and then monthly maintenance dose injections of 80 mg until such time as sufficient prostate reduction has occured (2-3 months) or they complete the 6 months of required androgen ablation for their disease status.
研究类型
介入性
注册 (实际的)
50
阶段
- 阶段2
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
British Columbia
-
Abbottsford、British Columbia、加拿大
- Abbottsford Cancer Center
-
Surrey、British Columbia、加拿大
- Fraser Valley Cancer Center
-
Vancouver、British Columbia、加拿大、V5Z4E6
- Vancouver Cancer Center
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
40年 至 80年 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
男性
描述
Inclusion Criteria:
- Histologic diagnosis of prostate cancer
- Favorable risk disease (cT1 or T2a, Gleason score (GS) 6, and Prostate Specific Antigen (PSA) < 10 ng/mL)
- Low-tier intermediate risk disease (cT2c,GS=6,and PSA 10-15 ng/mL, OR GS=7 and PSA < 10 ng/mL)
- Intermediate risk disease AND androgen deprivation therapy recommended by the treating physician for oncologic reasons such as (≥ 50% positive biopsy cores,cT2c,PSA 15-20 ng/mL,GS=7)
- Patient requires baseline planning trans-rectal ultrasound for the purposes of prostate brachytherapy, showing prostate volume > 40 mL and pubic arch interference (not required for those requiring androgen ablation for oncologic reasons)
Exclusion Criteria:
- castrate serum testosterone level
- previous or concurrent pelvic radiotherapy
- unable to give written informed consent
- contraindications to permanent seed prostate brachytherapy or to androgen deprivation therapy
- prior treatment for prostate cancer
- prior trans-urethral resection of the prostate
- previous therapy with a 5-α reductase inhibitor, anti-androgen agent, or LHRH agonist
- previous therapy with degarelix
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Favorable prostate cancer with pubic arch interference
Men in this arm have chosen brachytherapy for management of localized prostate cancer and do not require androgen ablation for oncologic reasons but have an enlarged prostate causing pubic arch interference and thus require prostate size reduction prior to brachytherapy.
They will have 2-3 months of Degarelix with measurement of prostate volume at 8 and 12 weeks.
|
240 mg loading dose followed by monthly 80 mg maintenance dose for 2-3 months
240 mg loading dose of Degarelix followed by 80 mg maintenance doses every month for a total duration of 6 months.
|
|
实验性的:Intermediate risk prostate cancer, 6 months Degarelix
Men in this arm have higher risk prostate cancer (upper tier intermediate risk by National Comprehensive Cancer Network [NCCN] guidelines) and require 6 months of androgen ablation in conjunction with brachytherapy.
Prostate size must be > 40 cc at baseline so that prostate size reduction measurements are appropriate.
Prostate measurements by transrectal ultrasound with be taken at 12 weeks and 20 weeks.
|
240 mg loading dose followed by monthly 80 mg maintenance dose for 2-3 months
240 mg loading dose of Degarelix followed by 80 mg maintenance doses every month for a total duration of 6 months.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
prostate volume reduction
大体时间:3 months
|
determined by transrectal ultrasound with planimetry volume calculation
|
3 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
testosterone recovery
大体时间:12 months
|
Luteinizing Hormone(LH), Follicle Stimulating Hormone (FSH) and testosterone will be measured at 1, 3, 6, 9 and 12 months following cessation of Degarelix.
|
12 months
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:Juanita M Crook, MD、British Columbia Cancer Agency
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2012年4月1日
初级完成 (实际的)
2017年2月1日
研究完成 (实际的)
2017年12月1日
研究注册日期
首次提交
2011年10月4日
首先提交符合 QC 标准的
2011年10月4日
首次发布 (估计)
2011年10月5日
研究记录更新
最后更新发布 (实际的)
2020年1月27日
上次提交的符合 QC 标准的更新
2020年1月23日
最后验证
2020年1月1日
更多信息
与本研究相关的术语
关键字
其他研究编号
- H11-08172
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
在美国制造并从美国出口的产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.